[1]李凤敏,顾玲玲,付建茹.非布司他与别嘌醇治疗高尿酸血症伴痛风的疗效比较[J].医学信息,2022,35(01):165-167.[doi:10.3969/j.issn.1006-1959.2022.01.041]
　LI Feng-min,GU Ling-ling,FU Jian-ru.Comparison of Febuxostat and Allopurinol in the Treatment of Hyperuricemia with Gout[J].Medical Information,2022,35(01):165-167.[doi:10.3969/j.issn.1006-1959.2022.01.041]
点击复制

非布司他与别嘌醇治疗高尿酸血症伴痛风的疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年01期
页码:
165-167
栏目:
药物与临床
出版日期:
2022-01-01

文章信息/Info

Title:
Comparison of Febuxostat and Allopurinol in the Treatment of Hyperuricemia with Gout
文章编号:
1006-1959（2022）01-0165-03
作者:
李凤敏; 顾玲玲; 付建茹
（天津市津南医院内科，天津 300350）
Author(s):
LI Feng-min; GU Ling-ling; FU Jian-ru
(Department of Internal Medicine,Tianjin Jinnan Hospital,Tianjin 300350,China)
关键词:
非布司他; 别嘌醇; 高尿酸血症; 痛风
Keywords:
Febuxostat; Allopurinol; Hyperuricemia; Gout
分类号:
R589.7
DOI:
10.3969/j.issn.1006-1959.2022.01.041
文献标志码:
A
摘要:
目的 比较非布司他与别嘌醇治疗高尿酸血症伴痛风的临床疗效。方法 选取2019年5月-2020年5月在我院诊治的62例高尿酸血症伴痛风患者为研究对象，采用随机数字表法分为对照组和观察组，各31例。对照组采用别嘌醇治疗，观察组给予非布司他治疗。比较两组临床疗效、不同时间段血清尿酸水平、血尿酸降低50%时间、血肌酐水平以及不良反应发生情况。结果 观察组治疗总有效率为87.10%，高于对照组的77.42%，差异有统计意义（P＜0.05）；治疗2、5个月，两组血清尿酸水平均低于治疗前，且观察组低于对照组，差异有统计意义（P＜0.05）；观察组平均血尿酸降低50%时间短于对照组，差异有统计意义（P＜0.05）；两组血肌酐水平均低于治疗前，且观察组低于对照组，差异有统计意义（P＜0.05）；观察组不良反应发生率低于对照组，差异有统计意义（P＜0.05）。结论 与别嘌醇比较，采用非布司他治疗高尿酸血症伴痛风效果理想，可提高治疗效果，降低血清尿酸和血肌酐水平，缩短血清尿酸降低时间，降低并发症发生率，有效性和安全性良好。
Abstract:
Objective To compare the clinical efficacy of febuxostat and allopurinol in the treatment of hyperuricemia with gout.Methods A total of 62 patients with hyperuricemia and gout who were treated in our hospital from May 2019 to May 2020 were selected as the research objects. They were divided into control group and observation group by random number table method, with 31 cases in each group. The control group was treated with allopurinol, and the observation group was treated with febuxostat. The clinical efficacy, serum uric acid level at different time points, 50% reduction of serum uric acid, serum creatinine level and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 87.10%, which was higher than 77.42% of the control group, and the difference was statistically significant (P<0.05). After 2 and 5 months of treatment, the serum uric acid levels in the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The average time of 50 % reduction of blood uric acid in the observation group was shorter than that in the control group, and the difference was statistically significant (P<0.05). The serum creatinine levels of the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05).Conclusion Compared with allopurinol, febuxostat has an ideal therapeutic effect on hyperuricemia with pain, which can improve the therapeutic effect, reduce serum uric acid and serum creatinine levels, shorten the time of serum uric acid reduction, and reduce the incidence of complications. It is effective and safe.

参考文献/References:

[1]张洋.非布司他治疗痛风伴高尿酸血症对炎症状态及血管内皮细胞功能的影响[J].中国药业,2016,25(21):49-51.[2]张晓燕,徐磊,李世大.非布司他与别嘌醇治疗痛风合并高尿酸血症疗效比较[J].中国基层医药,2019,26(6):738-740.[3]赵艳红.非布司他和别嘌呤醇治疗原发性痛风疗效和安全性的比较[J].浙江医学,2018,40(10):1088-1090.[4]Ghelich Khan Z,Talasaz AH,Pourhosseini H,et al.Potential role of allopurinol in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention：A randomized placebo-controlled trial[J].Clin Drug Investig,2017,37(9):853-860．[6]王海霞.非布司他联合塞来昔布治疗痛风性关节炎的临床疗效观察[J].中国药物与临床,2019,19(5):759-761.[7]陆玉鹏,李义凯,李益军,等.痛风定胶囊联合非布司他对高尿酸血症患者炎性因子的影响及其疗效[J].中国生化药物杂志,2016(1):59-61.[8]张旭红,林文果.降尿酸治疗在老年慢性肾脏病合并高尿酸血症患者中的应用[J].安徽医药,2018,22(10):1993-1996.[9]吴能森,杜小安.非布司他干预高尿酸血症、高脂血症的疗效观察[J].深圳中西医结合杂志,2018,28(15):171-172.[10]马沙,赵晓娜,张娟,等.痛风伴高尿酸血症及肾功能不全患者非布司他治疗剂量探讨[J].国际医药卫生导报,2018,24(20):3150-3152.[11]王惠芳,张伟,李宁,等.非布司他治疗慢性肾脏病3-5期伴高尿酸血症患者的疗效分析及对肾功能的影响[J].中华高血压杂志,2018,26(9):900．[12]Diaz-Torné C,Perez-Herrero N,Perez-Ruiz F.New medications in development for the treatment ofhyperuricemia of gout[J].Curr Opin Rheumatol,2015,27(2):164-169.[13]章娜,青玉凤,李婷,等.非布司他联合别嘌醇治疗高尿酸血症的效果及对血清 ET-1TGF-β1 水平的影响[J].中国老年学杂志,2019,39(5):1054-1057.[14]赵书山,王健,张正芳.非布司他治疗痛风伴高尿酸血症患者疗效的影响因素分析[J].现代实用医学,2019,31(1):42-44,141.[15]华明,孙朝珺.非布司他对比别嘌呤醇治疗慢性肾脏病合并高尿酸血症患者对于肾脏保护的作用[J].福建医科大学学报,2018,52(2):107-111.[16]霍晓聪,黄新翔,王曼,等.不同剂量非布司他与别嘌呤醇对痛风患者尿酸、NACHT-LRR-PYD结构域蛋白3及白细胞介素-1β水平影响的对比研究[J].广西医学,2018,40(4):378-381.

相似文献/References:

[1]李晓丽,任少辉,李雅然,等.递增降尿酸药物预防和减少痛风急性发作的疗效及安全性评估[J].医学信息,2022,35(18):30.[doi:10.3969/j.issn.1006-1959.2022.18.007]
　LI Xiao-li,REN Shao-hui,LI Ya-ran,et al.Efficacy and Safety Evaluation of Increasing Uric Acid Lowering Drugs to Prevent and Reduce Acute Gout Attacks[J].Medical Information,2022,35(01):30.[doi:10.3969/j.issn.1006-1959.2022.18.007]
[2]刘 星,刘璟琰,张思宇.维生素C联合非布司他对高尿酸血症伴痛风患者sICAM-1及尿酸的影响[J].医学信息,2020,33(07):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
　LIU Xing,LIU Jing-yan,ZHANG Si-yu.Effects of Vitamin C Combined with Febuxostat on sICAM-1 and Uric Acid in Patients with Hyperuricemia and Gout[J].Medical Information,2020,33(01):87.[doi:10.3969/j.issn.1006-1959.2020.07.024]
[3]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
　NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Medical Information,2020,33(01):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]

更新日期/Last Update: 1900-01-01